Assistant Professor of Radiation Oncology, Massachusetts General Hospital
Radiation Oncology
Dr. Jason A. Efstathiou, MD
|
|
Give Review
Jason A. Efstathiou works in the field of Radiation Oncology. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care Doctor Jason A. Efstathiou, MD is a published doctor and has 72 publications published. The lastest was: 'Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study.' Jason Efstathiou accepts Medicare payments and is listed with Medicare.gov.
Publications
- Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology.
- Global Radiation Oncology From the Trainee Perspective: A View From Beyond the Bunker.
- A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer.
- Treatment Trends for Prostate Cancer.
- Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base.
- Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana.
- Association between very small tumor size and increased cancer-specific mortality following radical prostatectomy in node-positive prostate cancer.
- Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility.
- Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.
- Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
- Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers.
- Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.
- Validation of a deformable image registration technique for cone beam CT-based dose verification.
- Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy...
- Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership.
- Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.
- EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells Against Ionizing Radiation.
- Outcomes in a Multi-institutional Cohort of Patients Treated With Intraoperative Radiation Therapy for Advanced or Recurrent Renal Cell Carcinoma.
- Medical Oncology Consultation and Minimization of Overtreatment in Men With Low-Risk Prostate Cancer.
- Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer.
- T1 high-grade bladder cancer recurring after BCG therapy: a curative alternative to radical cystectomy exists. Con.
- Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer.
- Trimodality bladder preservation therapy for muscle-invasive bladder cancer.
- Multidisciplinary care and management selection in prostate cancer.
- Hypofractionated proton therapy for prostate cancer: Dose delivery uncertainty due to interfractional motion.
- Practice-Based Evidence to Evidence-Based Practice: Building the National Radiation Oncology Registry.
- Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions.
- Proton Beam Radiation Therapy for Prostate Cancer-Is the Hype (and the Cost) Justified?
- Clinical controversies: proton therapy for prostate cancer.
- Physician Evaluation of Internet Health Information on Proton Therapy for Prostate Cancer.
- Maximizing dosimetric benefits of IMRT in the treatment of localized prostate cancer through multicriteria optimization planning.
- Nomograms Predicting Response to Therapy and Outcomes After Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
- Proton beam therapy and localised prostate cancer: current status and controversies.
- Prostate cancer: Proton therapy-revolutionary advance or diminishing returns?
- Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.
- The opportunity cost of androgen suppression in locally advanced prostate cancer.
- Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields.
- Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
- Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer.
- Postoperative radiation for prostate cancer.
- Urological cancer: The benefits of intermittent androgen-deprivation therapy.
- Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
- Reply to Neeraj Kumar Goyal, Manish Garg, and Apul Goel's Letter to the Editor re: Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-Term Out...
- Multidisciplinary Care and Pursuit of Active Surveillance in Low-Risk Prostate Cancer.
- Improvement of prostate treatment by anterior proton fields.
- Adjuvant radiation therapy for early stage seminoma: Proton versus photon planning comparison and modeling of second cancer risk.
- Reply from Authors re: Giuseppe Simone, Michele Gallucci. Multimodality Treatment Versus Radical Cystectomy: Bladder Sparing at Cost of Life? Eur Urol. In press. DOI:1...
- Complications and Long-Term Results of Salvage Cystectomy After Failed Bladder Sparing Therapy for Muscle Invasive Bladder Cancer.
- Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience.
- Evaluation of the dosimetric impact of interfractional anatomical variations on prostate proton therapy using daily in-room CT images.
- Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer.
- Comparison of High-Dose Proton Radiotherapy and Brachytherapy in Localized Prostate Cancer: A Case-Matched Analysis.
- Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for ...
- Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton ra...
- Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence.
- Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
- Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer.
- Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
- Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.
- Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
- Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.
- Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
- Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
- Endostatin inhibits the growth of endometriotic lesions but does not affect fertility.
- Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model.
- Endothelial-directed hepatic regeneration after partial hepatectomy.
- Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs.
- Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study.
- Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
- Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortalit...
- Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Schools
Harvard Medical School
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1598967523 | |
| NPPES Provider LastName | EFSTATHIOU | |
| NPPES Provider FirstName | JASON | |
| NPPES Provider ZIPCode | 02114 | |
| NPPES Provider State | MA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 21.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1598967523 |
| Last Name Of The Provider | EFSTATHIOU |
| First Name Of The Provider | JASON |
| View All |
Similar Doctors
|
|
Dr. Karl E. Haglund, MD |
|
|
Dr. Hani Al-Halabi, MDCM |
|
|
Dr. Kimberley S. Mak, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Konstantin A. Kovtun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniela L. Buscariollo, MD |
|
|
Dr. Andrea Ng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart M. Berman, MD |
|
|
Dr. Jay Loeffler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margarita Racsa Alamgir, MD |
|
|
Dr. Phillip M. Devlin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas F. Delaney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clair J. Beard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Akila Viswanathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas Kim, MD |